Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme

• Published in: Frontiers in immunology 2018-05, Vol.9, p.727-727
• Main Authors: Jan, Chia-Ing, Tsai, Wan-Chen, Harn, Horng-Jyh, Shyu, Woei-Cherng, Liu, Ming-Chao, Lu, Hsin-Man, Chiu, Shao-Chih, Cho, Der-Yang
• Format: Article
• Language: English
• Subjects: autologous dendritic cell/tumor antigen; glioblastoma multiforme; immune checkpoints; Immunology; peripheral blood mononuclear cell; programmed death protein 1 (PD-1+); tumor-infiltrating lymphocytes
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2018.00727

Glioblastoma (GBM) is the most common and lethal primary malignant glioma in adults. Dendritic cell (DC) vaccines have demonstrated promising results in GBM clinical trials. However, some patients do not respond well to DC therapy, with survival rates similar to those of conventional therapy. We retrospectively analyzed clinical and laboratory data to evaluate the factors affecting vaccine treatment. Forty-seven patients with GBM were enrolled at China Medical University Hospital between 2005 and 2010 and divided into two subgroups. One subgroup of 27 patients received postsurgical adjuvant immunotherapy with autologous dendritic cell/tumor antigen vaccine (ADCTA) in conjunction with conventional treatment of concomitant chemoradiotherapy (CCRT) with temozolomide. The other 20 patients received only postsurgical conventional treatment without immunotherapy. Immunohistochemistry for CD45, CD4, CD8, programed death ligand 1 (PD-L1), and programed death 1 (PD-1) was performed on sections of surgical tumor specimens and peripheral blood mononuclear cells (PBMCs). Pearson's correlation, Cox proportional hazard model, and Kaplan-Meier analyses were performed to examine the correlations between the prognostic factors and survival rates. Younger age (